Morgan, GeorgeBrighton, SarahLaffan, MichaelGoudemand, JennyFranks, BethanyFinnegan, Alan2022-08-192022-08-192022-08-17Morgan, G., Brighton, S., Laffan, M., Goudemand, J., Franks, B., & Finnegan, A. (2022). The cost of Von Willebrand Disease in Europe: The CVESS study. Clinical and Applied Thrombosis/Hemostasis, 28, Article number 10760296221120583. https://doi.org/10.1177/107602962211205831076-029610.1177/10760296221120583http://hdl.handle.net/10034/627091Background: Von Willebrand disease (VWD) is one of the most common inherited bleeding disorders, imposing a substantial health impact and financial burden. The Cost of von Willebrand disease in Europe: A Socioeconomic Study (CVESS) characterises the socio-economic cost of VWD across Germany, Spain, Italy, France, and the UK. Methods: A retrospective, cross-sectional design captured 12 months of patient disease management, collected from August-December 2018, for 974 patients. This enabled estimation of direct medical, direct non-medical and indirect costs, utilising prevalence estimates to extrapolate to population level. Results: Total annual direct medical cost (including/excluding von Willebrand factor [VWF]) across all countries was the highest cost (€2 845 510 345/€444 446 023), followed by indirect costs (€367 330 271) and direct non-medical costs (€60 223 234). Differences were seen between countries: the UK had the highest direct medical costs excluding VWF (€159 791 064), Italy the highest direct-non medical (€26 564 496), and Germany the highest indirect cost burden (€197 036 052). Total direct medical costs per adult patient increased across VWD types with Type 1 having the lowest cost (€23 287) and Type 3 having the highest cost (€133 518). Conclusion: A substantial financial burden arises from the prevalence of VWD for the European healthcare systems considered.Licence for this article starting on 2022-08-17: https://creativecommons.org/licenses/by-nc/4.0/Embargo: ends 2022-08-17https://creativecommons.org/licenses/by-nc/4.0/Von Willebrand diseasecostburdenEuropeArticle1938-2723Clinical and Applied Thrombosis/Hemostasis2022-08-19